



Accelerating Breakthroughs.
Delivering Results.
Transforming Lives.

Solve M.E. is a pioneer and leader in ME/CFS and Long Covid research, funding high-impact science that moves rapidly from discovery to real-world patient benefit. As the first private funder of ME/CFS research in the U.S., Solve deploys a strategic, portfolio-based approach designed for both immediate breakthroughs and long-term cures. Our research programs deliver a 66x return on investment, with over \$1.6M awarded grants to-date, yielding \$105M in follow-on funding.



The Solve ME/CFS Catalyst Awards: *Fast-Tracking Breakthroughs*

The Catalyst awards provide **strategic, rapid-response funding** for high-potential studies nearing key milestones, preventing promising research from stalling due to funding gaps. These awards accelerate **publication, clinical translation, and next-phase trials**, with a focus on **high-impact, near-term results**.



The Solve M.E. Ramsay Research Grant Program: *Building the Pipeline*

Solve provides seed funding for **innovative, early-stage research**, attracting new scientists to the field and supporting **pilot data generation** that unlocks major follow-on grants.



The unhide® Solve Together Unified Platform

Our **patient-centered, digital research platform** captures real-world data across **30+ chronic conditions**, including ME/CFS and Long Covid. The **unhide® Solve Together Unified Platform** integrates **symptom tracking, health history, and wearable data** to generate rich, longitudinal datasets for researchers and is designed to uncover **hidden connections between inflammation, chronic illness, and overall health**, accelerating new pathways to diagnosis and treatment.



Solve's research model funds science at **every critical stage**:

- **Early discovery (Ramsay Grants)** → builds evidence
- **Acceleration (Catalyst Awards)** → drives completion and translation
- **Real-world data + collaboration** → ensures relevance and scalability

This integrated approach means faster breakthroughs, lower risk, and a dramatically increased likelihood of delivering meaningful treatments to patients.

Solve turns donor dollars into exponential scientific impact.

